Price movement over the last 24 hours
ACADIA Pharmaceuticals Inc. vs Microchip Technology Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Microchip Technology Inc. trades at $85.6 (market cap $45.69B). The key difference: Microchip Technology Inc. is far larger — about 10.2× ACADIA Pharmaceuticals Inc.'s market cap, and Microchip Technology Inc. pays a 2.16% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MCHP | |
|---|---|---|
Market Cap | $4.49B | $45.69B |
Sector | Health | Technology |
52-Week High | $28.06 | $102.97 |
52-Week Low | $20.06 | $49.02 |
Enterprise Value | $3.69B | $50.99B |
Dividend Yield | — | 2.16% |
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Microchip Technology (MCHP) trades at $84.15, down 0.58% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 exceeding the $0.505 forecast. The company benefits from AI-driven semiconductor demand, aerospace and defense growth, and new product launches like the TimePictra 12 platform. However, 2025 saw a net loss of $500,000 on revenue of $4.40 billion, though 2026 projections indicate a return to profitability with a 4.88% net margin.
MCHP presents a mixed outlook: robust growth catalysts in AI and aerospace contrast with high valuation multiples (P/E of 398.14) and recent profitability challenges. The consensus price target of $115.45 suggests 37% upside, but investors face risks from debt levels and market volatility. The stock's near-term direction hinges on execution of its Q2 2026 earnings and sustained demand in key sectors.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →